A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer

NCT04619797 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

542

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG: Tiragolumab
DRUG: Atezolizumab
DRUG: Pemetrexed
DRUG: Carboplatin
DRUG: Cisplatin
DRUG: Tiragolumab Matching Placebo
DRUG: Pembrolizumab

Sponsor

Hoffmann-La Roche